octagam®5% | octagam®10% |
|---|---|
• Since 1995, octagam® has been helping to improve the lives of patients with immune disorders.¹˒² | • Optimised higher concentration formulation and higher maximum infusion rate, can provide added convenience.³˒⁴˒⁵ |
• A ready-to-use liquid IVIg with convenient room temperature storage (≤25°C).³˒⁴ | • Produced using the same reliable formulation.³˒⁴ |
What is octagam®?
Octagam® is a liquid, ready to use intravenous immunoglobulin (IVIg or IgIV) originally launched in 1995 as the first S/D treated (solvent/detergent) immunoglobulin from Octapharma. Today octagam® is available in two optimised concentrations, produced using a reliable formulation and manufacturing process, resulting in a very well tolerated immunoglobulin therapy which is available in more than 80 countries worldwide.1-7
The efficacy and tolerability of octagam® across multiple indications have been demonstrated through various clinical studies.1,3,4,6,7
Quality and safety are maintained through the robust manufacturing process.3,4
References
1. Frenzel W, et al. Tolerability and safety of octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54(11):847-855.
2. Debes A, et al. Tolerability and safety of the intravenous immunoglobulin octagam®: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf. 2007;16(9):1038-1047.
3. octagam®5%. Summary of Product Characteristics. May 2021.
4. octagam®10%. Summary of Product Characteristics. May 2021.
5. Robak et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam®10%) in patients with immune thrombocytopenia. Hematology. 2010; 15 (5): 351-359.
6. Ochs HD et al. octagam®5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol. 2004; 24(3): 309-314.
7. Wietek S et al. Tolerability and safety of the intravenous immunoglobulin octagam®10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials. Hematology. 2017; 1-6.
This is an international website for octagam® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website.
